Status:
COMPLETED
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Lead Sponsor:
Casa Sollievo della Sofferenza IRCCS
Collaborating Sponsors:
INMI L Spallanzani IRCCS Roma
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Liver Disease
Eligibility:
All Genders
18-70 years
Brief Summary
More than 1.5 millions individuals are infected with HCV in Italy. They are at risk to develop related morbidity and mortality from cirrhosis and hepatocellular carcinoma, unless the evolution of thei...
Detailed Description
This study is a prevalence study involving naïve patients and without links with treatment. Five hundred patients with HCV infection consecutively observed during 2011 will be requested to sign an inf...
Eligibility Criteria
Inclusion
- Patients with chronic HCV infection irrespective of HCV genotype
Exclusion
- HCV infected patients previously treated with antiviral drugs; co-infected Patients with HIV or Hepatitis B virus (HBsAg positive)
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01437969
Start Date
September 1 2011
End Date
September 1 2022
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS "Casa Sollievo della Sofferenza"
San Giovanni Rotondo, Foggia, Italy, 71013